Company News: Page (1) of 1 - 02/13/18 Email this story to a friend. email article Print this page (Article printing at page facebook

Phase II trial demonstrates activity of durvalumab in patients with recurrent or metastatic head and neck cancer

Results from randomized phase II CONDOR trial suggest the immune checkpoint blocker is safe and shows encouraging anti-tumor activity as second-line treatment in tumors with low/negative PD-L1; no dif... (February 13, 2018)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Pro AV,Presentors,Business Issues,Presentation,People,Training,Events,email, Inc.,Medicine,Disease,Cancer,Surgery,Medication,Science,Lifestyle,Medical,Biology,Physics,Cancer,Science,Email,Other,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved